最初的BMI对神经髓炎光学谱系障碍的临床表现和预后的影响
Wenqin Luo1, Xiaofei Wang1, Lingyao Kong1
1Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, PR China.
Annals of clinical and translational neurology
|July 27, 2023
概括
发病时的体重指数会影响神经omyelitis optica光谱障碍 (NMOSD) 的结果. 较低的BMI与较少的复发相关,但预后较差,突出显示BMI.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 流行病学 流行病学
背景情况:
- 神经脊髓炎光学谱系障碍 (NMOSD) 是一种罕见的自身免疫性疾病.
- 体重指数 (BMI) 是一种常见的健康指标,但其在NMOSD预后中的作用尚未完全理解.
研究的目的:
- 检查初始体重指数 (BMI) 和临床特征之间的关系.
- 评估BMI对神经髓炎光学谱系障碍 (NMOSD) 患者预后的影响.
主要方法:
- 从2015年1月到2022年1月,对246名NMOSD患者进行了回顾性队列研究.
- 患者在发病时按BMI进行分类;使用统计模型分析临床数据和结果.
- 考克斯和卡普兰-梅尔模型评估了BMI对复发风险和长期残疾的影响.
主要成果:
- 体重指数正常的患者在区域后热综合征的发病和复发频率较低.
- 较低的BMI与免疫抑制治疗后每年复发率显著降低有关.
- 多变量分析证实了BMI与复发风险,严重发作,视力障碍和整体残疾的相关性.
结论:
- 在神经omyelitis optica光谱障碍 (NMOSD) 患者的发病时的下体质指数 (BMI) 与不太频繁的复发有关.
- 尽管复发较少,但较低的BMI与NMOSD患者的长期预后较差以及残疾增加有关.
更多相关视频
08:05Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Published on: March 1, 2017
9.3K
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
11.5K
相关概念视频
01:15Myasthenia Gravis: Diagnostic Tests
1.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.0K
01:20Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K